Panama CNBI procedure checklist: Type II ethics, MINSA parallel track, RESEGIS, and import

Panama FIH calendars die on procedure, not on a missing brochure. Sponsors ask how to obtain MINSA approval for a medical device clinical trial and then treat ethics, CNBI registration, RESEGIS, and investigational import as a single checkbox. They are not.

I am Julio Martinez-Clark, CEO of bioaccess®. This is the Panama CNBI / Type II ethics + import logistics checklist drawn from clocks and instruments already published on our Panama hubs and ethics architecture page. It is not a quote and not a new statutory clock.

What “CNBI procedure” actually means

Ordinary ethics review in Panama runs through a Type II-accredited committee registered with the Comité Nacional de Bioética de la Investigación (CNBI). On our published ethics architecture page, ordinary ethics review is capped at 20 business days. High-risk protocols — Class III implants and novel biomaterials — open MINSA and Type II ethics in parallel, not as a forced serial queue under Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C).

CNBI registration of the committee is not the same file as MINSA authorization, and neither is RESEGIS study registration. Budget them as three lines.

Panama procedural checklist (sponsor-ready)

1. Confirm risk track. High-risk / Class III and novel biomaterial work belongs on the parallel MINSA + Type II ethics track. Do not price a serial ethics-then-authority plan if your device is on the high-risk path already described on our Panama Class III FIH materials.
2. Pick a CNBI-registered Type II committee that already reviews device protocols at the implanting hospital or network. Institutional committee first; national desk in parallel or after depending on track — see centralized vs decentralized ethics review.
3. Assemble the ethics packet in Spanish where the committee requires it: protocol, IB, IFU/training plan, consent, investigator docs, insurance certificate language the EC will accept. Insurance certificate timing is its own LATAM FIH bottleneck; do not assume the US binder travels unchanged.
4. File MINSA on the high-risk track in parallel with ethics when that is the published path — not “after CEI approval” by US habit.
5. Register in RESEGIS before start. Our ethics architecture page is explicit: register in RESEGIS before start on the Panama high-risk track. Public RESEGIS reporting is not a substitute for the authorization file.
6. Separate investigational import from ethics. Import logistics (permits, temperature, customs release, site receipt) sit on the Gantt next to ethics — see investigational device import as the LATAM FIH bottleneck. A 20-business-day ethics band does not move a device that is still on a dock.
7. Design for 21 CFR 812.28 inspectability from day one (English-reconstructable source, consent, monitoring). Panama speed is useless if FDA cannot reconstruct the file — see 812.28 inspectability.
8. If patients may continue after LPLV, open the PTA file early. Since 23 April 2026, Panama requires post-trial access under Decreto Ejecutivo 21/2026 Art. 68. Mechanism is import-permit extension framing, not a US “compassionate use” label — see Does Panama require post-trial access? and the Art. 68 pillar.

Import / logistics steps that belong on the same week plan

• Named importer of record for investigational units (trial import is not commercial registro).
• Lead times for apostille/legalization, Spanish labeling, and temperature-controlled lanes — use study-specific numbers; do not invent a Panama median here.
• Site receipt SOP and quarantine release before SIV.
• Endorsement path if a second country is added later (insurance and import), instead of pretending the Panama file automatically covers Country 2.

Common friction points

• Treating CNBI, MINSA, RESEGIS, and import as one “approval.”
• Serializing high-risk work that the published track opens in parallel.
• Pasting a Panama 3–5 week ethics band onto Brazil, Argentina, or Colombia calendars (our ethics page warns against that explicitly).
• Ignoring Art. 68 until a site asks who pays for continued supply.

Who does what (sponsor vs local stack)

• Sponsor: locks protocol/IB risk class, FDA strategy (including 812.28 inspectability), insurance limits, and whether Art. 68 continuation is in scope before first patient.
• Type II / CNBI-registered committee: ethics review of protocol, consent, and investigator packet on the ordinary or high-risk track.
• MINSA: national authorization path for the clinical investigation — parallel on high-risk, not a US-style afterthought.
• RESEGIS: study registration before start on the published high-risk track.
• Importer / logistics: investigational release into Panama and site receipt; later, if Art. 68 applies, the import-permit extension story for continued supply.

If one vendor claims to “own Panama approval” without naming those five lines, you do not yet have a procedure checklist — you have a slogan.

Clocks you may reuse — and clocks you may not invent

Reuse: CNBI/Type II ordinary ethics cap of 20 business days; high-risk parallel MINSA + ethics; Panama ethics bands already on the country hub and the Panama / El Salvador FIH cost vs US page. Do not invent a new MINSA day-count, a new per-patient average, or a new RESEGIS SLA on this page.

If you are choosing Panama for a Class III or biomaterial FIH, send bioaccess® the protocol stage, risk class, intended US filing, and target first-patient month. We will map CNBI committee, MINSA track, RESEGIS, import, and Art. 68 on one calendar — Global Trial Accelerators™ style, one accountable timeline.